ConductScience.org, home

Paper28642008

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.

Faivre-Finn C and 20 others. Lancet Oncol, 2017. Cited by 485 papers, by iCite.

Cite this record

ConductScience Library. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Papers, record 28642008. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28642008

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
PubMed
Journal
Lancet Oncol
PubMed
Year
2017
PubMed
Publication types
Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial
PubMed
Citations, by iCite
485
iCite
Relative citation ratio, by iCite
16.4
iCite
Revised in PubMed
2025-05-30
PubMed

Authors21

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Faivre-Finn CCorinne
2Snee MMichael
3Ashcroft LLinda
4Appel WWiebke
5Barlesi FFabrice
6Bhatnagar AAdityanarayan
7Bezjak AAndrea
8Cardenal FFelipe
9Fournel PPierre
10Harden SSusan
11Le Pechoux CCecile
12McMenemin RRhona
13Mohammed NNazia
14O'Brien MMary
15Pantarotto JJason
16Surmont VVeerle
17Van Meerbeeck JPJan P
18Woll PJPenella J
19Lorigan PPaul
20Blackhall FFiona

Source PubMed

See all 21 authorsDownload CSV of authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Lung NeoplasmsMajor topic
Small Cell Lung CarcinomaMajor topic
Adult
Aged
Aged, 80 and over
Chemoradiotherapy
Cisplatin
Dose Fractionation, Radiation
Esophagitis
Etoposide
Female
Follow-Up Studies
Humans
Intention to Treat Analysis
Male
Middle Aged
Neoplasm Staging
Neutropenia
Radiation Pneumonitis
Survival Rate

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
20465Cancer Research UKUnited KingdomPubMed
8154Cancer Research UKUnited KingdomPubMed

Source PubMed

Download CSV of grants

Trials4

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00433563Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung CancerDerived from the trialYesClinicalTrials.gov
NCT04696939Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer PatientsBackgroundClinicalTrials.gov
NCT05623267Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRTBackgroundClinicalTrials.gov
NCT06529081Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung CancerBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections9

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in28642007Which fractionation of radiotherapy is best for limited-stage small-cell lung cancer?https://conductscience.org/library/papers/28642007PubMed
Comment in28971812Is it time to convert the frequency of radiotherapy in small-cell lung cancer?https://conductscience.org/library/papers/28971812PubMed
Comment in28971813Is it time to convert the frequency of radiotherapy in small-cell lung cancer?https://conductscience.org/library/papers/28971813PubMed
Comment in28971814Is it time to convert the frequency of radiotherapy in small-cell lung cancer?https://conductscience.org/library/papers/28971814PubMed
Comment in28971815Is it time to convert the frequency of radiotherapy in small-cell lung cancer? - Authors' reply.https://conductscience.org/library/papers/28971815PubMed
Comment in29143097[Concurrent once-daily or twice-daily chemoradiotherapy in limited-stage small-cell lung cancer?]https://conductscience.org/library/papers/29143097PubMed
Comment in29208381CONVERTed or not: what are the barriers to implementing the evidence?https://conductscience.org/library/papers/29208381PubMed
Comment in29208382CONVERTed or not: what are the barriers to implementing the evidence? - Author's reply.https://conductscience.org/library/papers/29208382PubMed
Comment in29221253Twice-daily chemoradiotherapy must still be the choice for patients with limited-stage small-cell lung cancer.https://conductscience.org/library/papers/29221253PubMed

Download CSV of comments and corrections

References20

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115570087Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer.J Clin Oncol2004https://conductscience.org/library/papers/15570087PubMed
28622028Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.J Clin Oncol1996https://conductscience.org/library/papers/8622028PubMed
315561810A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer.Oncologist2004https://conductscience.org/library/papers/15561810PubMed
419652623
The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer.
J Thorac Oncol2009https://conductscience.org/library/papers/19652623PubMed
58381164Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.J Clin Oncol1993https://conductscience.org/library/papers/8381164PubMed
617008692Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.J Clin Oncol2006https://conductscience.org/library/papers/17008692PubMed
71331787A meta-analysis of thoracic radiotherapy for small-cell lung cancer.N Engl J Med1992https://conductscience.org/library/papers/1331787PubMed
87165009Toxicity and response criteria of the Eastern Cooperative Oncology Group.Am J Clin Oncol1982https://conductscience.org/library/papers/7165009PubMed
915674960Early versus late chest radiotherapy for limited stage small cell lung cancer.Cochrane Database Syst Rev2005https://conductscience.org/library/papers/15674960PubMed
109817271
Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
J Clin Oncol1998https://conductscience.org/library/papers/9817271PubMed
1123649448Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.Chest2013https://conductscience.org/library/papers/23649448PubMed
124580860Keynote address on biostatistics and data retrieval.Cancer Chemother Rep 31973https://conductscience.org/library/papers/4580860PubMed
1316344277Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer.Ann Oncol2006https://conductscience.org/library/papers/16344277PubMed
1423273996Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey.Int J Radiat Oncol Biol Phys2013https://conductscience.org/library/papers/23273996PubMed
159920950Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.N Engl J Med1999https://conductscience.org/library/papers/9920950PubMed
1626792218
Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.
BMJ Open2016https://conductscience.org/library/papers/26792218PubMed
1712654444Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis.Int J Radiat Oncol Biol Phys2003https://conductscience.org/library/papers/12654444PubMed
181316951Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis.J Clin Oncol1992https://conductscience.org/library/papers/1316951PubMed
1927436850Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis.Ann Oncol2016https://conductscience.org/library/papers/27436850PubMed
2016505424Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer.J Clin Oncol2006https://conductscience.org/library/papers/16505424PubMed

Download CSV of references

Cited by296

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 485 citations.

PMIDTitleJournalYearIn PapersSource
42907122Adebrelimab combined with apatinib and chemotherapy for neoadjuvant therapy and biomarker analysis in limited-stage small cell lung cancer: study protocol for a single-arm trial.BMJ Open2026https://conductscience.org/library/papers/42907122PubMed
42889196Survival and prognostic factors analysis of carbon ion radiotherapy for limited-stage small cell lung cancer.Front Oncol2026https://conductscience.org/library/papers/42889196PubMed
42840183The Five-Decade Journey of Small Cell Lung Cancer.Cancer Commun (Lond)2026https://conductscience.org/library/papers/42840183PubMed
42824004Romiplostim for refractory chemotherapy-induced thrombocytopenia in a long-term survivor of limited-stage small cell lung cancer: a case report.Front Oncol2026https://conductscience.org/library/papers/42824004PubMed
42823088Toripalimab consolidation after chemoradiotherapy in limited-stage small cell lung cancer: a phase II, randomized controlled study (GASTO-1052A).J Immunother Cancer2026https://conductscience.org/library/papers/42823088PubMed
42812441Impact of ALC Nadir and EDRIC on survival outcomes in limited-stage small cell lung cancer receiving chemoradiotherapy: a retrospective analysis comparing twice-daily and once-daily radiotherapy.Front Immunol2026https://conductscience.org/library/papers/42812441PubMed
42698800Neoadjuvant PD-1 Blockade Tislelizumab (BGB-A317) in Combination With Etoposide and Platinum-Based Chemotherapy for Limited-Disease Small Cell Lung Cancer.MedComm (2020)2026https://conductscience.org/library/papers/42698800PubMed
42643276ONC201 enhances the radiosensitivity of small-cell lung cancer via inhibition of the FAK signaling pathway.iScience2026https://conductscience.org/library/papers/42643276PubMed
42591674Consolidative thoracic radiotherapy following first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: A systematic review and meta-analysis.Ther Adv Med Oncol2026https://conductscience.org/library/papers/42591674PubMed
42583201Dose-escalated twice daily radiotherapy for limited stage small cell lung cancer: an implementation strategy in the Netherlands.J Thorac Dis2026https://conductscience.org/library/papers/42583201PubMed
42582865Real-world analysis in patients with limited-stage small-cell lung cancer who received durvalumab after concurrent chemoradiotherapy.Transl Lung Cancer Res2026https://conductscience.org/library/papers/42582865PubMed
42568026Small-Cell Lung Cancer: Biology, Translational Science and Clinical Innovation.Drugs2026https://conductscience.org/library/papers/42568026PubMed
42558713Efficacy and safety of immunotherapy combined with chemoradiotherapy in limited-stage small cell lung cancer: a systematic evaluation and meta-analysis of randomized controlled trials.Front Immunol2026https://conductscience.org/library/papers/42558713PubMed
42557939Chemotherapy and Radiotherapy Regimens for Limited-Stage Small Cell Lung Cancer Treated With Accelerated Hyperfractionated Radiotherapy Combined With Chemotherapy: A Real-World Study.Cancer Med2026https://conductscience.org/library/papers/42557939PubMed
42529258Durvalumab Consolidation Treatment Following Concurrent Chemoradiotherapy in Limited-Stage SCLC: ADRIATIC China Subgroup Analysis.JTO Clin Res Rep2026https://conductscience.org/library/papers/42529258PubMed
42364037Impact of weight loss on adverse events during chemoradiotherapy in patients with small cell lung cancer: a retrospective study.Support Care Cancer2026https://conductscience.org/library/papers/42364037PubMed
42337559A risk-adapted, dose-optimized esophagus-sparing radiation therapy technique for high-risk patients with lung cancer: feasibility, dosimetry, and acute esophageal toxicity.Radiat Oncol2026https://conductscience.org/library/papers/42337559PubMed
42306666Surgery versus radiotherapy after neoadjuvant immunochemotherapy in limited-stage small cell lung cancer.J Thorac Dis2026https://conductscience.org/library/papers/42306666PubMed
42303122Prophylactic Versus Therapeutic Sucralfate in Patients at High Risk for Radiation Esophagitis: Randomized Controlled Trial.Pract Radiat Oncol2026https://conductscience.org/library/papers/42303122PubMed
42279364Review of Management of Clinical Stage I Small Cell Lung Cancer: The Rising Role of Surgical Resection.Cancers (Basel)2026https://conductscience.org/library/papers/42279364PubMed

See all 296 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28642008

GET https://conductscience.org/api/papers/v1/28642008/authors?page=2